28 April 2020
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces further positive interim data from its ongoing Phase II TACTI-002 study. The data relates to the data cut-off date of 20 March 2020 and shows improving efficacy results.
The results are being presented today as a poster short talk audio presentation as part of the high-impact paper presentation program by TACTI-002 Principle Investigator, Dr Martin Forster of University College London Hospitals NHS Foundation at the American Association for Cancer Research (AACR) Virtual Annual Meeting.
TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). It is evaluating the combination of the Company’s lead product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD’s KEYTRUDA® (pembrolizumab) in up to 109 patients with second line HNSCC or NSCLC in first and second line.
Immutep CSO and CMO, Dr Frederic Triebel said: “These very positive results for stage 1 demonstrate the benefits for NSCLC patients in receiving efti in combination with pembrolizumab. 53% of patients are now responding and we expect PFS to be more than 9 months. These consolidated results, with more tumour responses being confirmed by a second CT-scan and a longer follow up, are remarkable given that usually only 20% of patients respond to pembrolizumab monotherapy, if not pre-selected for high PD-L1 expression. It is also encouraging to see that 33% of HNSCC patients are responding, almost double the proportion that respond to pembrolizumab monotherapy and that the median PFS hasn’t yet been reached for this group.”
Read the full media release.